Physician profile
Alisha Gupta
NPI 1750764114
$9,344.81
in general payments reported to CMS, 2019-2025
30 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,445 · 2023: $2,885 · 2024: $2,808 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,899.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,214.72 | 2022-2025 | |
| Amgen INC. | $1,351.63 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Glaxosmithkline, LLC. | $866.64 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $751.34 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $722.07 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $486.61 | 2022-2025 | Taltz, Zepbound |
| Ucb, INC. | $436.52 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $427.46 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $327.14 | 2022-2025 | Saphnelo |
| Organon LLC | $283.15 | 2022-2025 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.92 | 2023-2025 | Ofev, Cyltezo |
| Janssen Biotech, INC. | $224.30 | 2022-2024 | Tremfya, Remicade, Simponi Aria |
| Boston Scientific Corporation | $141.93 | 2024 | Wavewriter Alpha Prime 16 |
| Sobi, INC | $140.62 | 2022-2025 | |
| United Therapeutics Corporation | $95.46 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $81.63 | 2023-2025 | Actemra, Gazyva |
| Actelion Pharmaceuticals US, INC. | $79.20 | 2023-2024 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $78.66 | 2025 | |
| Fresenius Kabi USA, LLC | $77.06 | 2023-2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $68.23 | 2024-2025 | Orencia |
| Sandoz INC. | $50.22 | 2024-2025 | Jubbonti, Hyrimoz |
| Novo Nordisk INC | $50.00 | 2024 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $22.55 | 2024 | Zilretta, Iovera |
| Argenx US, INC. | $21.56 | 2025 | Vyvgart Hytrulo |
| Fidia Pharma USA INC. | $19.97 | 2025 | Hymovis |
| Mylan Institutional INC. | $18.23 | 2023 | |
| Daiichi Sankyo INC. | $16.65 | 2023 | Injectafer |
| Kyowa Kirin, INC. | $16.51 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.62 | 2022 | |
| Genzyme Corporation | $15.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.